NCT06008704Recruiting
Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)
Pathophysiology of Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)
Source: ClinicalTrials.gov · Last updated 11 May 2026
Brief summary (registry, in English)
This project will explore the involvement of the serotonin system in the pathophysiology of PD-related central pain. Thus, the serotonin system will be evaluated in PD patients with and without central pain who will benefit from brain positron emission tomography (PET) allowing in vivo imaging of 5HT1A receptors and multimodal brain MRI including morphometric imaging and functional connectivity (resting state acquisition).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- First submitted
- 10 May 2023
- Start date
- 1 Jan 2024
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- University Hospital, Toulouse
- Diseases
- Parkinson disease
- NCT number
- NCT06008704
- EudraCT number
- 2022-501123-24
What you commit to
- Study type: Interventional
- Planned participants: 34
- From 1 Jan 2024 to the primary completion date, 1 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients treated with second line therapy
- Patients treated with drugs interacting with 5HT1A receptors in the previous 4 weeks
Other illness
- Patients with a history of significant psychiatric pathology according to the investigator
Other
- Patients with contraindication to MRI
- Patients refusing to be informed of an abnormality discovered during brain imaging
- Patients with dyskinesias judged by the investigator to be disabling for imaging.
- Patients under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision
- Pregnant woman, breastfeeding woman
Who the study is looking for
- Patients with PD defined according to United Kingdom Parkinson's Disease Brain Bank (UKPDSBB) criteria
- Patients with stable anti-parkinsonian treatment for at least 4 weeks prior to inclusion
- Patients with a Montreal Cognitive Assessment (MoCA) score \> 25
- Patients with a Hospital Anxiety and Depression Scale (HADS)-D score ≥ 11
- Person affiliated or benefiting from a social security scheme.
- Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
- For patients with pain
- Patients with PD-related central pain defined according to the criteria of Marques et al, 2019
- Patients with chronic central pain (i.e. present for at least 3 months)
- Patients who have average pain over the previous month according to a VAS ≥ 4.
- For patients without pain
- Patients who do not have pain defined as VAS ≤ 4, meaning that it does not interfere with daily activity.
Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Hospitalier Universitaire de Toulouse Coordinator of this site? Confirm its status | Toulouse | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.